在恶性疾病中的C1抑制剂.

Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency<sup>1</sup>.

Clinical and experimental immunology·2020

Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype.

Clinical and experimental immunology·2015

Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro.

Clinical and experimental immunology·2014

Tissue-and metal-specific effects of thiolacrylic acids in rats.

Biological trace element research·2013

The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals.

QJM : monthly journal of the Association of Physicians·2012

Preparing serum for functional complement assays.

Journal of immunological methods·2009

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

Przeglad menopauzalny = Menopause review·2026

BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

Health science reports·2026

Classical Hodgkin Lymphoma Today.

Mediterranean journal of hematology and infectious diseases·2026

Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

Frontiers in pharmacology·2026

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

Frontiers in pharmacology·2026

Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

Frontiers in immunology·2026

相关实验视频

在恶性疾病中的C1抑制剂.

相关概念视频

Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency<sup>1</sup>.

Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype.

Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro.

Tissue-and metal-specific effects of thiolacrylic acids in rats.

The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals.

Preparing serum for functional complement assays.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

Classical Hodgkin Lymphoma Today.

Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

相关实验视频

在恶性疾病中的C1抑制剂.

相关概念视频

相关文章